IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients
暂无分享,去创建一个
Derek E. Smith | Kimberly R. Jordan | M. McCarter | D. Gao | K. Lewis | V. Borges | S. Robinson | C. Amato | R. Gonzalez | W. Robinson | K. Jordan | V. Vorwald | R. Tobin | K. Couts | D. Davis | P. Kapoor | Eric Spongberg | J. Borgers | Dana M Davis | Victoria M. Vorwald | Victoria M Vorwald
[1] Kimberly R. Jordan,et al. Targeting myeloid‐derived suppressor cells using all‐trans retinoic acid in melanoma patients treated with Ipilimumab , 2018, International immunopharmacology.
[2] V. Simeon,et al. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. , 2018, Cancer letters.
[3] S. Katz,et al. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells , 2018, Oncogene.
[4] Dong Wang,et al. Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1/RelA/IL8 Signaling Pathway , 2018, Cancer Immunology Research.
[5] S. Senju,et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. , 2018, Cancer research.
[6] Darren R. Williams,et al. Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion , 2018, Clinical Cancer Research.
[7] J. Utikal,et al. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors , 2018, Front. Immunol..
[8] Huidong Shi,et al. Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen‐Presenting Cells in Tumors , 2018, Immunity.
[9] Rui Zhang,et al. Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer , 2017, Front. Immunol..
[10] Kristen K. McCampbell,et al. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. , 2017, JCI insight.
[11] Kimberly R. Jordan,et al. The clinical evidence for targeting human myeloid‐derived suppressor cells in cancer patients , 2017, Journal of leukocyte biology.
[12] R. Halaban,et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] J. Barquinero,et al. Myeloid‐derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes , 2017, Immunology and cell biology.
[14] K. Flaherty,et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition , 2017, The Journal of experimental medicine.
[15] Yan Zhang,et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer , 2017, Oncotarget.
[16] Kimberly R. Jordan,et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients , 2017, Cancer Immunology, Immunotherapy.
[17] D. Gabrilovich. Myeloid-Derived Suppressor Cells , 2017, Cancer Immunology Research.
[18] D. Fearon,et al. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity , 2016, Cell metabolism.
[19] J. Wargo,et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.
[20] Peter J. Murray,et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.
[21] A. Biankin,et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma , 2016, Cancer cell.
[22] M. Sade-Feldman,et al. Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab , 2016, Clinical Cancer Research.
[23] I. Melero,et al. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) , 2016, Clinical Cancer Research.
[24] W. Yuan,et al. G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers , 2016, Protein & Cell.
[25] D. Linehan,et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.
[26] B. Sangro,et al. Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins , 2014, Clinical Cancer Research.
[27] V. Borges,et al. Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. , 2014, The Journal of clinical investigation.
[28] James T. Webber,et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. , 2014, Cell reports.
[29] T. Yen,et al. IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus , 2014, Oncotarget.
[30] Hong-Wei Sun,et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients , 2014, Proceedings of the National Academy of Sciences.
[31] Daniel T. Fisher,et al. The two faces of IL-6 in the tumor microenvironment. , 2014, Seminars in immunology.
[32] Kimberly R. Jordan,et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients , 2013, Cancer Immunology, Immunotherapy.
[33] Ming Li,et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.
[34] S. Lang,et al. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer , 2013, Innate immunity.
[35] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[36] H. Zhang,et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.
[37] N. Jhala,et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.
[38] Takami Sato,et al. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.
[39] D. Latchman,et al. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters , 2000, Cell Death and Differentiation.